mgmt methylation testing Search Results


mgmt methylation status analysis  (MDxHealth)
90
MDxHealth mgmt methylation status analysis
Patients from the Nordic trial included in the study. Patients with good prognostic factors were selected from each treatment arm (temozolomide -TMZ, radiotherapy 34Gy-RT 34Gy, and radiotherapy 60Gy- RT60Gy). Half of the tumors had methylated <t>MGMT</t> promoter (m-MGMT), and half had unmethylated MGMT promoter (u-MGMT). These patients were further divided into long-term survivors (LTS) and short-term survivors (STS). N, number of patients.
Mgmt Methylation Status Analysis, supplied by MDxHealth, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mgmt+methylation+testing/mgmt+promoter+methylation+testing/pmc09452748-50-1-8
Average 90 stars, based on 1 article reviews
mgmt methylation status analysis - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
mgmt methylation testing  (LabCorp)
90
LabCorp mgmt methylation testing
Cox Regression Analysis of Overall Survival and Progression-Free Survival of 102 Primary Glioblastoma <t> MGMT </t> Unmethylated Patients With Substratification by <t> MGMT </t> Values
Mgmt Methylation Testing, supplied by LabCorp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mgmt+methylation+testing/mgmt+methylation+testing/pmc06656311-97-12-17
Average 90 stars, based on 1 article reviews
mgmt methylation testing - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Patients from the Nordic trial included in the study. Patients with good prognostic factors were selected from each treatment arm (temozolomide -TMZ, radiotherapy 34Gy-RT 34Gy, and radiotherapy 60Gy- RT60Gy). Half of the tumors had methylated MGMT promoter (m-MGMT), and half had unmethylated MGMT promoter (u-MGMT). These patients were further divided into long-term survivors (LTS) and short-term survivors (STS). N, number of patients.

Journal: Frontiers in Genetics

Article Title: Methylation associated with long- or short-term survival in glioblastoma patients from the Nordic phase 3 trial

doi: 10.3389/fgene.2022.934519

Figure Lengend Snippet: Patients from the Nordic trial included in the study. Patients with good prognostic factors were selected from each treatment arm (temozolomide -TMZ, radiotherapy 34Gy-RT 34Gy, and radiotherapy 60Gy- RT60Gy). Half of the tumors had methylated MGMT promoter (m-MGMT), and half had unmethylated MGMT promoter (u-MGMT). These patients were further divided into long-term survivors (LTS) and short-term survivors (STS). N, number of patients.

Article Snippet: The MGMT methylation status was analyzed with the MDxHealth method, Liège, Belgium, as mentioned in ).

Techniques: Methylation

Patient characteristics.

Journal: Frontiers in Genetics

Article Title: Methylation associated with long- or short-term survival in glioblastoma patients from the Nordic phase 3 trial

doi: 10.3389/fgene.2022.934519

Figure Lengend Snippet: Patient characteristics.

Article Snippet: The MGMT methylation status was analyzed with the MDxHealth method, Liège, Belgium, as mentioned in ).

Techniques: Biomarker Discovery, Methylation

Pie charts representing the structural genomic distribution of DMCs discovered in samples with long ( n = 3) and short ( n = 3) survival within the different treatment arms and with specified MGMT promoter methylation status. TSS200, 200 bases upstream transcription start site; TSS1500, 1,500 bases upstream transcription start site; UTR, untranslated region; IGR, intergenic region; 60Gy34Gy, combined RT.

Journal: Frontiers in Genetics

Article Title: Methylation associated with long- or short-term survival in glioblastoma patients from the Nordic phase 3 trial

doi: 10.3389/fgene.2022.934519

Figure Lengend Snippet: Pie charts representing the structural genomic distribution of DMCs discovered in samples with long ( n = 3) and short ( n = 3) survival within the different treatment arms and with specified MGMT promoter methylation status. TSS200, 200 bases upstream transcription start site; TSS1500, 1,500 bases upstream transcription start site; UTR, untranslated region; IGR, intergenic region; 60Gy34Gy, combined RT.

Article Snippet: The MGMT methylation status was analyzed with the MDxHealth method, Liège, Belgium, as mentioned in ).

Techniques: Methylation

Cox Regression Analysis of Overall Survival and Progression-Free Survival of 102 Primary Glioblastoma MGMT Unmethylated Patients With Substratification by MGMT Values

Journal: Neuro-Oncology Practice

Article Title: Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival

doi: 10.1093/nop/npy028

Figure Lengend Snippet: Cox Regression Analysis of Overall Survival and Progression-Free Survival of 102 Primary Glioblastoma MGMT Unmethylated Patients With Substratification by MGMT Values

Article Snippet: In this retrospective study, we sought to examine whether the magnitude of MGMT methylation as determined by LabCorp 4 testing (versus a single stratification based on a cutoff of 2) better correlates with outcome in our GBM patients from 2011 to 2016.

Techniques: Biomarker Discovery

Kaplan-Meier analysis is used to A, compare the MGMT (1-1.99) vs MGMT (<1) and MGMT (≥2) patients. The MGMT (1-1.99) group’s median OS (25.4 months) falls in between the MGMT (≥2) (38.8 months) and MGMT (<1) (17.3 months) median OS values (Log-rank P = .001). B, PFS showed the same trend, namely the MGMT (1-1.99) group generated a higher median OS of 11.8 months compared to the MGMT (<1) group but lower than the MGMT (≥ 2) group, yielding 11.8 months vs 7.92 months and 18.0 months (Log-rank P < .0001), respectively. MGMT indicates O-6-methylguanine-DNA methyltransferase; mo, months; OS, overall survival; PFS, progression-free survival.

Journal: Neuro-Oncology Practice

Article Title: Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival

doi: 10.1093/nop/npy028

Figure Lengend Snippet: Kaplan-Meier analysis is used to A, compare the MGMT (1-1.99) vs MGMT (<1) and MGMT (≥2) patients. The MGMT (1-1.99) group’s median OS (25.4 months) falls in between the MGMT (≥2) (38.8 months) and MGMT (<1) (17.3 months) median OS values (Log-rank P = .001). B, PFS showed the same trend, namely the MGMT (1-1.99) group generated a higher median OS of 11.8 months compared to the MGMT (<1) group but lower than the MGMT (≥ 2) group, yielding 11.8 months vs 7.92 months and 18.0 months (Log-rank P < .0001), respectively. MGMT indicates O-6-methylguanine-DNA methyltransferase; mo, months; OS, overall survival; PFS, progression-free survival.

Article Snippet: In this retrospective study, we sought to examine whether the magnitude of MGMT methylation as determined by LabCorp 4 testing (versus a single stratification based on a cutoff of 2) better correlates with outcome in our GBM patients from 2011 to 2016.

Techniques: Generated

Cox Regression Analysis of Overall Survival and Progression-Free Survival of 165 Primary Glioblastoma Patients With Substratification by MGMT Values

Journal: Neuro-Oncology Practice

Article Title: Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival

doi: 10.1093/nop/npy028

Figure Lengend Snippet: Cox Regression Analysis of Overall Survival and Progression-Free Survival of 165 Primary Glioblastoma Patients With Substratification by MGMT Values

Article Snippet: In this retrospective study, we sought to examine whether the magnitude of MGMT methylation as determined by LabCorp 4 testing (versus a single stratification based on a cutoff of 2) better correlates with outcome in our GBM patients from 2011 to 2016.

Techniques: Biomarker Discovery